HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Lowers Price Target to $27
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Cogent Biosciences (NASDAQ:COGT) but lowers the price target from $28 to $27.
June 08, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Cogent Biosciences (NASDAQ:COGT) but lowers the price target from $28 to $27.
The news of HC Wainwright maintaining a Buy rating on Cogent Biosciences is positive for the stock. However, the lowering of the price target from $28 to $27 may have a neutralizing effect on the stock price in the short term, as it indicates a slightly reduced growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100